

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	Э.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/016,979		12/12/2001	Reid Burton Kowallis	4406C1	4406C1 6772	
22896	7590	06/29/2004		EXAMINER		
	,	ATENT DEPT.	HANDY, DWAYNE K			
APPLIED BIOSYSTEMS 850 LINCOLN CENTRE DRIVE				ART UNIT	PAPER NUMBER	
FOSTER (CITY, CA	94404		1743		
				DATE MAILED: 06/29/200	4	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
·	10/016,979	KOWALLIS, REID	BURTON
Office Action Summary	Examiner	Art Unit	
	Dwayne K Handy	1743	
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence add	dress
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	nely filed s will be considered timely the mailing date of this co D (35 U.S.C. § 133).	
Status	•		
1) Responsive to communication(s) filed on 12 De			
2a) This action is FINAL . 2b) ☐ This	action is non-final.		
3) Since this application is in condition for allowan	•		merits is
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	i3 O.G. 213.	
Disposition of Claims		·	
4) Claim(s) 29-39 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 29-39 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	in from consideration.		
Application Papers			
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the orange Replacement drawing sheet(s) including the correction of the orange representation is objected to by the Examiner.	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CF	, ,
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National S	Stage
Attachment(s)			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4)		
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 12/12/2001.		ratent Application (PTO	-152)

Application/Control Number: 10/016,979

Art Unit: 1743

DETAILED ACTION

Double Patenting

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 29-38 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-4 and 15-18 of U.S. Patent No. 6,245,297. Although the conflicting claims are not identical, they are not patentably distinct from each other. In claim 29, applicant has claimed a spotting system comprised of a base having one or more areas adapted to hold reagents, a conveyor positioned over the base and having a plurality of substrate support areas and a plurality of openings allowing access to the base, a transfer head movable along an axis, and one of more controllers. In claim 34 the transfer head is mounted. These claims are broader than the cited claims of U.S. Patent 6,245,297. The cited claims from the patent contain the features of the instant claims as well as additional elements. Therefore, the instant claims are anticipated by the patented claims.

Page 3

Application/Control Number: 10/016,979

Art Unit: 1743

3. Claim 39 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 6,355,487. Although the conflicting claims are not identical, they are not patentably distinct from each other. In claim 39 applicant has claimed a method for accessing a reagent held at a reagent supply location under a plurality of substrates comprised of the steps of advancing a plurality of spaced substrates along a pathway extending over the reagent supply location and then extending a reagent transfer instrument from a position above the reagent supply and pathway through an intervening region separating an adjacent pair of substrates to contact the reagent supply. This claim is broader than the cited claims of U.S. Patent 6,355,487. The cited claim from the patent contains the steps of the instant claim as well as additional steps. Therefore, the instant claims are anticipated by the patented claims.

Conclusion

4. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Franzen (6,696,302) teach a contamination free transfer device. Kimura et al. (6,458,582) show a fixing device for applying a sheet to the openings of reaction containers. Studer et al. (6,251,686) teach an apparatus for transferring liquids. Fassbind et al. (6,156,575) teach a sample processing system. Wray et al. (4,057,145) show a medication dispenser.

Application/Control Number: 10/016,979

Art Unit: 1743

Page 4

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dwayne K Handy whose telephone number is (571)-

272-1259. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jill Warden can be reached on (571)-272-1267. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

DKH June 26, 2004

Julii Warden
Supervisory Patent Examiner
Technology Center 1700